{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:33:17Z","timestamp":1761129197033},"reference-count":27,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":257,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurourol. Urodynam."],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1002\/nau.22712","type":"journal-article","created":{"date-parts":[[2014,12,19]],"date-time":"2014-12-19T09:29:18Z","timestamp":1418981358000},"page":"267-270","source":"Crossref","is-referenced-by-count":19,"title":["Preliminary results of botulinum toxin A switch after first detrusor injection failure as a treatment of neurogenic detrusor overactivity"],"prefix":"10.1002","volume":"35","author":[{"given":"Benoit","family":"Peyronnet","sequence":"first","affiliation":[{"name":"D\u00e9partement d'Urologie, Transplantation R\u00e9nale et Andrologie; CHU Rangueil; Toulouse France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathieu","family":"Roumigui\u00e9","sequence":"additional","affiliation":[{"name":"D\u00e9partement d'Urologie, Transplantation R\u00e9nale et Andrologie; CHU Rangueil; Toulouse France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyne","family":"Castel-Lacanal","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Physique et R\u00e9adaptation; CHU Rangueil; Toulouse France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Guillotreau","sequence":"additional","affiliation":[{"name":"D\u00e9partement d'Urologie, Transplantation R\u00e9nale et Andrologie; CHU Rangueil; Toulouse France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Malavaud","sequence":"additional","affiliation":[{"name":"D\u00e9partement d'Urologie, Transplantation R\u00e9nale et Andrologie; CHU Rangueil; Toulouse France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Marque","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Physique et R\u00e9adaptation; CHU Rangueil; Toulouse France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Rischmann","sequence":"additional","affiliation":[{"name":"D\u00e9partement d'Urologie, Transplantation R\u00e9nale et Andrologie; CHU Rangueil; Toulouse France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Gam\u00e9","sequence":"additional","affiliation":[{"name":"D\u00e9partement d'Urologie, Transplantation R\u00e9nale et Andrologie; CHU Rangueil; Toulouse France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,12,18]]},"reference":[{"key":"10.1002\/nau.22712-BIB0001|nau22712-cit-0001","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1002\/nau.22631","article-title":"Chapter 4: Guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO)","volume":"33","author":"Nambiar","year":"2014","journal-title":"Neurourol Urodyn"},{"key":"10.1002\/nau.22712-BIB0002|nau22712-cit-0002","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/01.ju.0000162035.73977.1c","article-title":"Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: Results of a single treatment, randomized, placebo controlled 6-month study","volume":"174","author":"Schurch","year":"2005","journal-title":"J Urol"},{"key":"10.1002\/nau.22712-BIB0003|nau22712-cit-0003","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1016\/j.juro.2011.02.004","article-title":"Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: A randomized, double-blind trial","volume":"185","author":"Herschorn","year":"2011","journal-title":"J Urol"},{"key":"10.1002\/nau.22712-BIB0004|nau22712-cit-0004","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.juro.2012.01.125","article-title":"Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity","volume":"187","author":"Ginsberg","year":"2012","journal-title":"J Urol"},{"key":"10.1002\/nau.22712-BIB0005|nau22712-cit-0005","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.eururo.2011.07.002","article-title":"Efficacy and safety of onabotulinumtoxin A in patients with urinary incontinence due to neurogenic detrusor overactivity: A randomised, double-blind, placebo-controlled trial","volume":"60","author":"Cruz","year":"2011","journal-title":"Eur Urol"},{"key":"10.1002\/nau.22712-BIB0006|nau22712-cit-0006","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1002\/nau.22630","article-title":"Chapter 5: Clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB)","volume":"33","author":"Cruz","year":"2014","journal-title":"Neurourol Urodyn"},{"key":"10.1002\/nau.22712-BIB0007|nau22712-cit-0007","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1111\/j.1464-410X.2006.06091.x","article-title":"What is the optimum dose of type A botulinum toxin for treating neurogenic bladder overactivity?","volume":"97","author":"Ruffion","year":"2006","journal-title":"BJU Int"},{"key":"10.1002\/nau.22712-BIB0008|nau22712-cit-0008","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/00365590601068835","article-title":"Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: A randomised, placebo-controlled, double-blind study","volume":"41","author":"Ehren","year":"2007","journal-title":"Scand J Urol Nephrol"},{"key":"10.1002\/nau.22712-BIB0009|nau22712-cit-0009","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.eururo.2011.10.043","article-title":"Prospective randomised controlled trial comparing trigone-sparing versus trigone-including intradetrusor injection of abobotulinumtoxinA for refractory idiopathic detrusor overactivity","volume":"61","author":"Manecksha","year":"2012","journal-title":"Eur Urol"},{"key":"10.1002\/nau.22712-BIB0010|nau22712-cit-0010","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.eururo.2011.07.001","article-title":"Contemporary management of lower urinary tract disease with botulinum toxin A: A systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA)","volume":"60","author":"Mangera","year":"2011","journal-title":"Eur Urol"},{"key":"10.1002\/nau.22712-BIB0011|nau22712-cit-0011","unstructured":""},{"key":"10.1002\/nau.22712-BIB0012|nau22712-cit-0012","unstructured":"2014 http:\/\/www.uroweb.org\/gls\/pdf\/21%20Neuro-Urology_LR.pdf"},{"key":"10.1002\/nau.22712-BIB0013|nau22712-cit-0013","unstructured":"2009 http:\/\/www.ics.org\/Publications\/ICI_4\/files-book\/recommendation.pdf"},{"key":"10.1002\/nau.22712-BIB0014|nau22712-cit-0014","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1002\/nau.22637","article-title":"Chapter 6: Practical aspects of administration of onabotulinumtoxinA","volume":"33","author":"Rovner","year":"2014","journal-title":"Neurourol Urodyn"},{"key":"10.1002\/nau.22712-BIB0015|nau22712-cit-0015","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1002\/mds.20066","article-title":"Clinical comparability of marketed formulations of botulinum toxin","volume":"19","author":"Sampaio","year":"2004","journal-title":"Mov Disord"},{"key":"10.1002\/nau.22712-BIB0016|nau22712-cit-0016","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0302-2838(03)00250-1","article-title":"Botulinum toxin as a new therapy option for voiding disorders: Current state of the art","volume":"44","author":"Leippold","year":"2003","journal-title":"Eur Urol"},{"key":"10.1002\/nau.22712-BIB0017|nau22712-cit-0017","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1468-1331.2006.01438.x","article-title":"Pharmacology of botulinum toxin: Differences between type A preparations","volume":"13","author":"Rosales","year":"2006","journal-title":"Eur J Neurol"},{"key":"10.1002\/nau.22712-BIB0018|nau22712-cit-0018","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1464-410X.2009.08466.x","article-title":"Comparing two types of botulinum-A toxin detrusor injections in patients with severe neurogenic detrusor overactivity: A case-control study","volume":"104","author":"Grosse","year":"2009","journal-title":"BJU Int"},{"key":"10.1002\/nau.22712-BIB0019|nau22712-cit-0019","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/mds.870120627","article-title":"DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A-Dysport and Botox-assuming a ratio of 4:1","volume":"12","author":"Sampaio","year":"1997","journal-title":"Mov Disord"},{"key":"10.1002\/nau.22712-BIB0020|nau22712-cit-0020","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/jnnp.64.1.6","article-title":"A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia","volume":"64","author":"Odergren","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1002\/nau.22712-BIB0021|nau22712-cit-0021","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1046\/j.1365-2036.1999.00602.x","article-title":"Comparison of two different formulations of botulinum toxin A for the treatment of oesophageal achalasia. The Gismad Achalasia Study Group","volume":"13","author":"Annese","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1002\/nau.22712-BIB0022|nau22712-cit-0022","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1002\/mds.20012","article-title":"Pharmacokinetic properties of different formulations of botulinum neurotoxin type A","volume":"19","author":"Wohlfarth","year":"2004","journal-title":"Mov Disord"},{"key":"10.1002\/nau.22712-BIB0023|nau22712-cit-0023","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1007\/s00415-008-0031-7","article-title":"Biological activity of two botulinum toxin type A complexes (Dysport and Botox) in volunteers: A double-blind, randomized, dose-ranging study","volume":"255","author":"Wohlfarth","year":"2008","journal-title":"J Neurol"},{"key":"10.1002\/nau.22712-BIB0024|nau22712-cit-0024","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.eururo.2012.01.051","article-title":"Minimal effective dose of dysport and botox in a rat model of neurogenic detrusor overactivity","volume":"61","author":"Behr-Roussel","year":"2012","journal-title":"Eur Urol"},{"key":"10.1002\/nau.22712-BIB0025|nau22712-cit-0025","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.juro.2010.12.002","article-title":"Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-A for detrusor overactivity in patients with multiple sclerosis","volume":"185","author":"Khan","year":"2011","journal-title":"J Urol"},{"key":"10.1002\/nau.22712-BIB0026|nau22712-cit-0026","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/iju.12205","article-title":"Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity","volume":"21","author":"Veeratterapillay","year":"2014","journal-title":"Int J Urol"},{"key":"10.1002\/nau.22712-BIB0027|nau22712-cit-0027","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.eururo.2011.12.011","article-title":"Repeated botulinum toxin type A injections for refractory overactive bladder: Medium-term outcomes, safety profile, and discontinuation rates","volume":"61","author":"Dowson","year":"2012","journal-title":"Eur Urol"}],"container-title":["Neurourology and Urodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fnau.22712","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/nau.22712","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T21:25:59Z","timestamp":1625347559000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/nau.22712"}},"subtitle":["Preliminary Results of Botulinum Toxin A Switch"],"short-title":[],"issued":{"date-parts":[[2014,12,18]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"URL":"https:\/\/doi.org\/10.1002\/nau.22712","archive":["Portico"],"relation":{},"ISSN":["0733-2467"],"issn-type":[{"value":"0733-2467","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12,18]]}}}